<DOC>
	<DOC>NCT00705172</DOC>
	<brief_summary>This study is conducted in Europe. The aim of this observational study is to collect data from children with Prader-Willi Syndrome, who have been treated off-label with Norditropin® for more than 12 months to seek approval for Norditropin® treatment with Prader-Willi Syndrome.</brief_summary>
	<brief_title>Retrospective Observational Study on Efficacy and Safety of Norditropin® in Children With Prader-Willi Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Prader-Willi Syndrome</mesh_term>
	<criteria>Informed consent obtained before any trialrelated activities Genetically diagnosed PraderWilli Syndrome Received at least one dose of Norditropin® treatment Prepubertal at start of treatment; assessed by Tanner stage 1, or testicular volume below 4ml (according to Tanner 1976) Pretreatment with other Growth Hormone preparation prior to treatment with Norditropin®</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>